A phase 3 study of ALKS 3831 idemonstrated greater antipsychotic efficacy compared with placebo, as measured by rating scales, according to a poster presented at Psych Congress 2018.
A phase 3 study of ALKS 3831 demonstrated greater antipsychotic efficacy compared with placebo, as measured by rating scales, according to a poster presented at Psych Congress 2018.
ALKS 3831 is composed of a flexible dose of olanzapine (OLZ) and a fixed dose of 10 mg samidorphan (SAM), an opioid receptor antagonist, formulated as a bilayer tablet. It is being studied for the treatment of schizophrenia to mitigate the weight gain and metabolic effects associated with olanzapine alone.
In a phase 2 study, coadministration of SAM mitigated OLZ-associated weight gain, and the OLZ + SAM combination exhibited antipsychotic efficacy similar to OLZ alone.
Preclinical studies have provided evidence for a role of the opioid system in mediating food reward, feeding behavior and metabolism.
The efficacy of ALKS 3831 and OLZ were similar. However, due to baseline differences between groups with regard to body mass index (BMI), the acute nature of the population, and the short duration of the trial, it was difficult to compare weight gain between groups. Long-term studies to examine the effects on weight and other metabolic measures are continuing.
The study consisted of a 4-week treatment phase of 2 weeks of inpatient treatment (OLZ titration permitted) followed by 2 weeks of inpatient/outpatient treatment (fixed OLZ dose).
Patients were admitted to the trial if they had a primary diagnosis of acute exacerbation of schizophrenia but excluded if they had a primary psychiatric diagnosis other than schizophrenia, or received OLZ within 6 months prior to screening. Antipsychotic efficacy was assessed using the Positive and Negative Syndrome Scale (PANSS), and Clinical Global Impression—Severity (CGI-S) and CGI–improvement (CGI-I) scales
The primary endpoint, change from baseline in PANSS total score at week 4, was analyzed using a mixed model with repeated measurements (MMRM). The key secondary endpoint, change from baseline in CGI-S score at week 4, was also analyzed by MMRM. The proportions of PANSS responders and CGI-I responders were analyzed by a logistic regression model. PANSS response was defined as ≥30% improvement from baseline in PANSS total score, and CGI-I response was defined as a CGI-I score of ≤2.
In total, 401 patients were randomized and given ALKS 3831, OLZ, or placebo. The mean age was 41 years and 61% of patients were male. Baseline mean BMI was higher in the OLZ group compared with the ALKS 3831 and placebo groups (27.4 kg/m2, 26.4 kg/m2, and 25.9 kg/m2, respectively).
Overall baseline mean ± standard deviation (SD) scores were 101.7 ± 11.9 for PANSS total score and 5.1 ± 0.7 for CGI-S score. The mean OLZ dose was 18.4 mg/day in both active treatment arms. The least squares (LS) mean difference ± standard error (SE) versus placebo from baseline to week 4 in PANSS total score was −6.4 ± 1.8 (P < .001) and −5.3 ± 1.8 (P = .004) for the ALKS 3831 and OLZ groups, respectively.
Change from baseline in PANSS total score by week (MMRM) LS mean difference ± SE versus placebofrom baseline to week 4 in CGI-S score was −0.38 ± 0.12 (P = .002) and −0.44 ± 0.12 (P < .001) for the ALKS 3831 and OLZ groups, respectively
The proportions of PANSS responders at week 4 were statistically significantly greater for ALKS 3831 (59.8%; P < .001) and OLZ (53.8%; P = .015) compared with placebo (38.3%). The proportions of CGI-I responders at week 4 were statistically significantly greater for ALKS 3831 (57.6%; P < .001) and OLZ (50.8%; P = .004) compared with placebo (33.1%).
Common adverse events included weight gain, somnolence, dry mouth, anxiety, headache, and schizophrenia. The most common reason for discontinuation was withdrawal by patient. One patient who was treated with OLZ died of a heroin overdose shortly after completing treatment.
The study was funded by Alkermes.
Reference
Potkin SG, Kunovac J, Silverman BL, et al. A phase 3 study to determine the antipsychotic efficacy and safety of ALKS 3831 in adult patients with acute exacerbation of schizophrenia. Presented at Psych Congress 2018, October 25-28, 2018, Orlando, Florida. Poster 129.
ATS 2024: Bridging the Past, Present, and Future of Respiratory Care
May 16th 2024The application of artificial intelligence in medicine is anticipated as a highlight of ATS 2024, with sessions exploring its applications in research, radiological interpretation, and pediatric pulmonology.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Looking Back on ISPOR 2024: Hot Policy Topics, Welcome Focus on Employers, and More
May 10th 2024Kimberly Westrich, MA, chief strategy officer of the National Pharmaceutical Council, reflects on the most valuable learnings from the 2024 meeting of ISPOR—The Professional Society for Health Economics and Outcomes Research, including lively discussions of the Inflation Reduction Act and workshops on value assessment.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More
A Focus on Women: AUA Best Posters Highlight Female Athletes, Prenatal Care, and Women in Urology
May 9th 2024Three posters from the American Urological Association (AUA) 2024 Annual Meeting focused on urinary incontinence in female athletes, prenatal care for fetuses with spina bifida in California, and the experiences of women residents at the Brady Urological Institute.
Read More